1-4 of 4
Per-Olof Thuresson
Close
Sort by
Journal Articles

Exploring the Impact of Diffuse Large B-Cell Lymphoma (International Prognostic Index [IPI] 2-5) on Clinical and Patient-Relevant Outcomes in the Context of a Clinical Trial

Aino Launonen, Rodrigo Ho, Andrea Knapp, Irene Canales Ruiz, Leonardo Simonella, Per-Olof Thuresson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3577.
https://doi.org/10.1182/blood-2021-146822
Published: 2021
Journal Articles

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Felipe Castro, Andy Surinach, MPH, Aino Launonen, Per-Olof Thuresson, Federico Felizzi
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-137529
Published: 2020
Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4767.
https://doi.org/10.1182/blood-2019-123688
Published: 2019
Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5603.
https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603
Published: 2017